- EQT VII acquires Certara, the global leader in model-informed (in silico) drug development and regulatory science, focused on optimizing drug development and improving health outcomes
- Certara’s solutions help to inform and accelerate drug development and regulatory approval processes, while addressing the key efficacy, safety, productivity and commercial challenges facing the biopharma industry
- EQT VII to support Certara’s growth trajectory by leveraging EQT’s operational and financial resources, including its global network of industrial advisors and deep expertise within the healthcare and pharmaceutical services sectors
Princeton, NJ and New York, NY, July 11, 2017 – The EQT VII fund (“EQT VII”) today announced that it has agreed to acquire Certara (the “Company”), the leading provider of technology-driven decision support solutions for drug development, for an enterprise value of USD 850 million. The Company is being acquired from Arsenal Capital Partners. As part of the transaction, Arsenal Capital Partners will retain a minority ownership stake in Certara, with the Company’s current management team, led by Edmundo Muniz, MD, PhD, continuing to lead the organization, building on a multi-year track record of both organic growth and strategic acquisitions.
Certara is the leading provider of model-informed drug development technology and services, as well as a best-in-class provider of regulatory science, writing, and submission management software and services. Certara’s solutions help inform the drug development and regulatory approval process and address the key efficacy, safety, productivity and commercial challenges facing the biopharma industry. The Company serves 1,200 commercial companies, 250 academic institutions and numerous regulatory agencies, across 60 countries. Certara is headquartered in Princeton, New Jersey with over 500 employees globally, including key operations and senior management in Northern Europe.
Eric Liu, Partner at EQT Partners, Investment Advisor to EQT VII said: “We are deeply impressed by what the Certara management team has accomplished over the last few years. Today, Certara is the global leader in an exciting and rapidly developing market, uniquely positioned to transform the field of drug development. Under Edmundo’s leadership the Company has assembled a strong and visionary management team and a highly-talented scientific staff, while fostering a mission-driven culture and accelerating growth. We are excited to support the development of Certara through continued investment in next generation technology, further international expansion and complementary acquisitions.”
“We are excited to team up with EQT as we look toward Certara’s next phase of growth,” said Edmundo Muniz, MD, PhD and CEO of Certara. “This new strategic partnership with EQT will enable us to strengthen our core offerings as well as to capitalize on transformative next-phase growth opportunities. We are looking forward to a great partnership that will benefit our customers, our employees, and our industry.”
Centerview Partners is serving as financial advisor and Simpson Thacher & Bartlett LLP is serving as legal advisor to EQT VII. Jefferies LLC is serving as lead financial advisor and William Blair & Company as co-advisor to Certara. DLA Piper and Morgan, Lewis & Bockius LLP are serving as legal advisors to Certara.